Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

275P - Serological response to COVID-19 vaccine in patients with advanced breast cancer

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Pablo Casado Cuesta

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101224-101224. 10.1016/esmoop/esmoop101224

Authors

P. Casado Cuesta1, F. Pikabea Díaz1, E. Galve-Calvo1, A. ZUMARRAGA1, A. Bilbao Penas1, B. López De San Vicente1, C. Figaredo Bejarano1, I. Bernat Pina2, J. Legaspi1, J.R. Barceló Galíndez1, L. Sande Sardina1, M. NuÑo Escolastico1, M.T. Abad Villar1, M. Lopez Santillan3, M.T. Pérez Hoyos1, M.A. Sala Gonzalez1, M. Temiño Francés1, P.L. Loaiza Jaramillo1, J.L. Díaz de Tuesta del Arco1, P. Martinez del Prado1

Author affiliations

  • 1 Hospital Universitario de Basurto, Bilbao/ES
  • 2 Basurto, Barakaldo/ES
  • 3 Hospital de Basurto, Bilbao/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 275P

Background

Patients (p) with solid tumor have an increased risk of severe coronavirus disease 2019 (COVID-19) and associate higher mortality compared to general population. Cancer patients were not included in pivotal trials of COVID-19 vaccines. A high proportion of p with solid tumors develop immunological responses following vaccination, and subsequent doses can result in seroconversion in those who were previously seronegative after the two first doses. In Advanced Breast Cancer (ABC) p knowledge of vaccine effects is scarce.

Methods

Prospective observational study analysed the serological response to COVID-19 vaccine in a series of patients (p) with ABC treated in a single institution. Between 01/03/2021 and 19/05/2021 we analysed the serological response by serial determination of COVID-19 antibodies (Ab) 21 or 28 days after each dose and 3, 6, 9 and 12 months (m) after the second dose. We considered an antibody titration of 2500 total Ig/ml as a robust antibody response (RAR).

Results

N=43 p. with ABC, 100% female; median age: 69 years (y). Comorbidity: 29 p (67%) hypertension, 6 p (14%) active smoking. Histological subtype: 21 p (49%) luminal, 19 p (44%) Her2 + and 3 p (7%) triple negative (TN). Treatment: 2 p (5%) chemotherapy (CT), 3 p (7%) immunotherapy and 29 p (88%); First-line: 20 p (48%), 2ndline 8 p (19%), 3rdor successive line 14 p (33,4)[MMDP1]. A previous COVID-19 infection: 1 p (2,3%); In the period of study 8 p were tested positive for COVID-19. Type of vaccine: Pfizer/BioNTech (Comirnaty): 33 p (78%) and Moderna (Spikevax) 10 p (23%). Adverse effects: 2 p (4.7%) with one requiring hospitalization (2.3%). After the first vaccine, 2/32 p (6.3%) had RAR. Following a second dose, the RAR rose to 8/35 p (23%). At 3 and 6 m after the second dose a RAR was observed in 4/23 p (17.4 %) and 10/25 p (40%) respectively. A 3rddose increased the RAR robust to 13/16 p ( 81%), and in those receiving a 4thvaccine (9/43) 77.8% achieved a robust Ab response. At the end of the follow-up, 7 p (16%) (7/43) died of cancer. The efficacy of vaccines was similar to general population regardless of cancer diagnosis and treatments.

Conclusions

In our series of ABC patients tested for COVID-19 vaccine seroconversion, a robust serological response was shown especially after the 3rdand 4thdose (in up to 80% of patients).

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

E. Galve-Calvo: Financial Interests, Personal, Invited Speaker: AstraZeneca, Daiichi Sankyo, Gilead, Novartis, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.